Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3375880 IV
LY3375880 · 2 trials · 1 indication
The pain VAS is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's pain is indicated by placing a single mark on the scale from 0 mm (no pain) to 100 mm (severe pain).
PK: Cmax of LY3375880
PK: AUC of LY3375880
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Part A: LY3375880 Formulation A | EXPERIMENTAL | LY3375880 Formulation A administered subcutaneously (SC). |
| Part A: LY3375880 Formulation B | EXPERIMENTAL | LY3375880 Formulation B administered subcutaneously SC. |
| Part A: LY3375880 Formulation C | EXPERIMENTAL | LY3375880 Formulation C administered SC. |
| Part A: Positive Control | PLACEBO_COMPARATOR | Positive Control (buffer matrix, only) administered SC. |
| Part B: LY3375880 Test 1 | EXPERIMENTAL | LY3375880 Test 1 Formulation administered SC. |
| Part B: LY3375880 Test 2 | EXPERIMENTAL | LY3375880 Test 2 Formulation administered SC. |
| Part B: LY3375880 Test 3 | EXPERIMENTAL | LY3375880 Test 3 Formulation administered SC. |
| LY3375880 Single Dose | EXPERIMENTAL | Single dose of LY3375880 administered IV or SC |
| Placebo Single Dose | PLACEBO_COMPARATOR | Single dose of placebo administered IV or SC |
| LY3375880 Multiple Dose | EXPERIMENTAL | Multiple doses of LY3375880 administered IV or SC |
| Placebo Multiple Dose | PLACEBO_COMPARATOR | Multiple doses of placebo administered IV or SC |
| Name | Type | Description |
|---|---|---|
| LY3375880 | DRUG | Administered SC |
| Buffer Matrix (No LY3375880) | DRUG | Administered SC |
| Autoinjector (AI) | DEVICE | AI used to administer LY3375880 or Buffer Matrix |
| Manual Syringe | DEVICE | Manual syringe used to inject LY3375880 |
| LY3375880 IV | DRUG | administered IV |
| LY3375880 SC | DRUG | administered SC |
| Placebo IV | DRUG | administered IV |
| Placebo SC | DRUG | administered SC |
Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination * Have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²) inclusive * Females who are not of child-bearing potential * Males who agree to use a reliable method of...
LY3375880 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in Phase 1 clinical trials in healthy adult participants in the United States. The specific disease or condition it is intended to treat has not been publicly disclosed.
LY3375880 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored both Phase 1 trials of the compound conducted in the United States.
LY3375880 is in Phase 1 development. Two Phase 1 trials have been completed, and no active trials are currently listed. The compound has been tested only in healthy volunteers, and no later-stage studies have been reported.
LY3375880 has been evaluated in two completed Phase 1 trials: NCT03913260, which studied different injectable formulations in 83 healthy participants, and NCT03343587, which studied the drug in 80 healthy participants. Both were conducted in the United States and together enrolled 163 participants.
Yes. LY3375880 IV is an alternative name for LY3375880, reflecting the injectable formulations studied in its clinical program. Searches for either name refer to the same Eli Lilly investigational small molecule.
Both Phase 1 trials of LY3375880 were randomized, double-blind, and placebo-controlled, enrolling a total of 163 healthy adult participants aged 18 and older. One trial compared different injectable formulations, and the other evaluated the drug in healthy participants.